Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies

Caris Life Sciences (NASDAQ: CAI) launched Caris ChromoSeq on April 2, 2026: a combined Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay for myeloid malignancies.

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) launched Caris ChromoSeq on April 2, 2026: a combined Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay for myeloid malignancies.

The test delivers ~250x genome read depth, 40 million transcriptome reads, supports bone marrow or peripheral blood samples, and has an expected seven-day turnaround.

Positive

• Single-test profiling replaces multiple myeloid diagnostic assays
• 250x genomic read depth for enhanced variant detection
• 40 million transcriptome reads for greater RNA resolution
• Seven-day expected turnaround to accelerate clinical decisions

Negative

• Intended only for myeloid malignancies (AML, MDS, MPN) limiting addressable scope
• Requires bone marrow aspirate or peripheral blood samples for testing

Argus Apr 2 session

+0.84% close to close Open Argus

Details

News Market Reaction – CAI

On Apr 2, the day this news came out, CAI closed 0.84% above the previous close.

Data tracked by StockTitan Argus for the Apr 2 session.

Market Context

This announcement expands Caris Life Sciences’ whole genome and whole transcriptome capabilities int...

Analysis

This announcement expands Caris Life Sciences’ whole genome and whole transcriptome capabilities into myeloid malignancies, offering 250x genomic coverage, 40 million transcriptome reads, and a 7-day turnaround in a single assay. It builds on recent Caris Detect and GPSai studies and the company’s large multimodal datasets. Investors can watch how quickly ChromoSeq integrates into real-world workflows and how it contributes to utilization trends highlighted in prior clinical and AI-focused updates.

Key Figures

Genome read depth: 250x Transcriptome reads: 40 million reads Turnaround time: 7 days +5 more

Genome read depth

250x

Caris ChromoSeq whole genome sequencing read depth

Transcriptome reads

40 million reads

Caris ChromoSeq whole transcriptome sequencing coverage

Turnaround time

7 days

Expected reporting time for Caris ChromoSeq assay

Cytopenia duration

more than four months

Threshold for suspected myeloid malignancy use case

Achieve 1 subjects

3,014 subjects

Caris Detect multi-cancer early detection study enrollment

Stage I–II sensitivity

60.3%

Achieve 1 Caris Detect Stage I–II overall sensitivity

Multimodal dataset size

over 500,000 patients

Caris multimodal dataset for AI Insights training

Oncology cases sequenced

over 1,000,000 cases

Total oncology cases sequenced as of Dec 31, 2025

Historical Context

5 past events · Latest: Mar 31

5 events

1. Mar 31

   Clinical study results

   24h Move

   +7.0%

   Final Achieve 1 data showing strong sensitivity and specificity for Caris Detect.

2. Mar 26

   AI product expansion

   24h Move

   -1.2%

   New AI Insights signatures for brain metastasis risk in breast and NSCLC.

3. Mar 25

   Conference presentations

   24h Move

   -3.5%

   Announcement of six oncology studies using proprietary multimodal data at AACR 2026.

4. Mar 24

   Diagnostic testing focus

   24h Move

   -0.1%

   Emphasis on DPYD testing integrated into Caris Assure blood-based sequencing assay.

5. Mar 20

   AI diagnostic study

   24h Move

   -2.1%

   GPSai study showing reclassification of misdiagnosed cancers and treatment changes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

whole genome sequencing, myeloid malignancies, acute myeloid leukemia, myelodysplastic syndromes, +3 more

7 terms

whole genome sequencing medical

"Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole Transcriptome..."

Whole genome sequencing is a laboratory method that reads an individual’s complete DNA instruction book, capturing all genetic letters rather than just selected parts. For investors, it matters because it can reveal new ways to diagnose, prevent or treat disease and to develop tests or drugs — like upgrading from a map of a few streets to a full city blueprint — which can create commercial opportunities, influence regulatory pathways and change healthcare costs and demand.

myeloid malignancies medical

"assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies."

Myeloid malignancies are cancers that start in the bone marrow’s myeloid cell line, which produces red blood cells, certain white blood cells and platelets; examples include forms of leukemia and related blood disorders. For investors, they matter because they define a set of diseases that create demand for diagnostics, treatments and long-term care; breakthroughs or regulatory setbacks in this area can change market size and revenue prospects for biotech and pharmaceutical companies much like a new product can reshape a company’s sales outlook.

acute myeloid leukemia medical

"intended for use in acute myeloid leukemia (AML), myelodysplastic syndromes..."

A fast‑moving blood cancer that starts in the bone marrow and crowd out healthy blood cell production, leaving the body short of normal red cells, white cells and platelets. It matters to investors because the disease creates urgent medical need, drives demand for new diagnostics and treatments, and so clinical trial results, regulatory decisions and drug pricing can rapidly change the commercial prospects and valuation of companies working on therapies.

myelodysplastic syndromes medical

"use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative..."

Myelodysplastic syndromes are a group of disorders in which the bone marrow — the body’s blood cell factory — makes blood cells that are abnormal or too few, leading to anemia, infections, or bleeding and sometimes progressing to leukemia. Investors monitor them because demand for effective drugs, clinical trial results, and regulatory approvals can materially affect the revenues and valuations of healthcare companies and influence projected treatment costs and market opportunities.

myeloproliferative neoplasms medical

"myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as in patients..."

Myeloproliferative neoplasms are a group of blood cancers caused by the bone marrow producing too many of one or more types of blood cells, which can crowd out normal cells and impair blood flow. Investors pay attention because these conditions create clear medical needs and predictable markets for diagnostics, therapies and follow-up care—similar to a failing factory that creates demand for repair services and replacement parts—affecting drug development, regulatory milestones and potential sales.

bone marrow aspirate medical

"resolution from a bone marrow aspirate or peripheral blood collection."

A bone marrow aspirate is a small sample of the liquid portion of bone marrow taken with a needle to examine blood-forming cells and detect disease. Think of it like taking a core sample of soil to see what’s growing and whether the ground is healthy; results guide diagnoses, treatment decisions, and the progress of therapies. Investors care because aspirate findings affect drug development, regulatory filings, trial outcomes, and commercial prospects for treatments targeting blood or immune disorders.

peripheral blood medical

"resolution from a bone marrow aspirate or peripheral blood collection."

Peripheral blood is the blood circulating through a person’s veins and arteries that is commonly drawn from a limb for laboratory tests and analyses, as opposed to blood still inside organs or bone marrow. For investors it matters because many diagnostic tests, clinical trial measurements, and cell-based therapies rely on samples from peripheral blood—like checking highway traffic to judge overall system health—so results can affect trial outcomes, regulatory decisions, and commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Ultra-deep Whole Genome and Transcriptome Sequencing provides a more complete workup for myeloid malignancies with clearer, faster diagnostic insight

IRVING, Texas, April 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced the launch of Caris ChromoSeq™, a Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), as well as in patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months, where other potential causes have been reasonably excluded.

Myeloid malignancies are among the most genetically complex cancers, often requiring multiple tests to identify clinically relevant mutations, structural variants and chromosomal abnormalities. This fragmented approach can delay critical treatment decisions and miss detection of important genomic alterations used for diagnosis and risk stratification.

Caris ChromoSeq can replace the multiple test protocols of the myeloid diagnostic workflow, complementing the clinician's overall clinical and pathological evaluation. Building on this foundation, the test delivers approximately 250x read depth across the genome with 40 million transcriptome reads, enabling enhanced genomic resolution from a bone marrow aspirate or peripheral blood collection. Results are synthesized into a single, easy‑to‑interpret, actionable report to support confident, timely clinical decision‑making, with an expected seven-day turnaround time.

"The Caris ChromoSeq launch provides an unprecedented amount of genomic and transcriptomic data per patient, enabling a complete diagnostic evaluation in a single test. Never before have patients and physicians had access to a technology with the depth and breadth provided by Caris ChromoSeq," said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris. "This launch reflects our commitment to delivering a single, integrated genomic solution for patients with hematological cancers that fits into real‑world clinical workflows and provides results fast enough to inform patient care."

The launch of Caris ChromoSeq underscores Caris Life Sciences' ongoing focus on advancing precision medicine through innovative molecular profiling technologies that simplify complexity and support clinicians across the cancer care continuum. 

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-announces-launch-of-caris-chromoseq-the-worlds-first-whole-genome-and-whole-transcriptome-tumor-profiling-assay-for-myeloid-malignancies-302732465.html

SOURCE Caris Life Sciences

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Caris ChromoSeq and which myeloid diseases does CAI target with it?

Caris ChromoSeq is a combined WGS and WTS diagnostic assay for myeloid cancers. According to the company, it is intended for AML, MDS, MPN and suspected myeloid malignancies with unexplained cytopenia lasting more than four months.

What sequencing depth and transcriptome coverage does Caris ChromoSeq (CAI) provide?

The assay provides approximately 250x read depth and 40 million transcriptome reads. According to the company, these metrics enable enhanced genomic and transcriptomic resolution from bone marrow or peripheral blood samples.

How fast are results from Caris ChromoSeq for investors considering CAI's clinical offerings?

Caris expects an approximate seven-day turnaround for test results. According to the company, results are synthesized into a single, actionable report to support timely clinical decision-making.

Can Caris ChromoSeq replace existing myeloid diagnostic workflows for clinicians and CAI customers?

The test is designed to replace multiple myeloid testing protocols with one assay. According to the company, it complements clinical and pathological evaluation and consolidates findings into one easy-to-interpret report.

What specimen types are required for Caris ChromoSeq and are there sample limitations for CAI's assay?

Caris ChromoSeq accepts bone marrow aspirate or peripheral blood samples for testing. According to the company, sample type requirements aim to support routine hematology workflows but limit use to obtainable specimen types.